{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-23-000020","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.694474+00:00","generated_at":"2026-06-16T00:44:22.023998+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pacira Q1 total revenue $160.3M; net loss $19.5M; EXPAREL sales $130.4M","bullets":["Total revenues $160.3M vs $158.0M in Q1 2022, up 1.5%; GAAP net loss $0.43/share vs net income $0.15/share.","EXPAREL net product sales $130.4M, avg daily volumes up 6%, offset by 340B pricing; ZILRETTA $24.3M; iovera° $4.0M.","Adjusted EBITDA $41.9M vs $53.8M in Q1 2022; non-GAAP net income $24.3M ($0.53 diluted share).","FDA accepted sNDA for EXPAREL lower-extremity nerve blocks; PDUFA date Nov 13, 2023.","Repaid $287.5M Term Loan B using $150M new Term Loan A and cash; appointed Christopher Young Chief Manufacturing Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-23-000020","json":"https://secwatch.observer/filing/0001396814-23-000020.json","markdown":"https://secwatch.observer/filing/0001396814-23-000020.md","text":"https://secwatch.observer/filing/0001396814-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000020/0001396814-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000020/pcrx-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T00:44:22.023998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a1ed414d348ce47a1b34c7ca2968d798ea19985","claim":"Pacira BioSciences, Inc. reported the first quarter of 2023 results: revenue $160.3 million, net income $19.5 million, EPS $0.43 per share (basic and diluted). Guidance reaffirmed.","evidence_excerpt":"pain management and regenerative health solutions, today reported financial results for the first quarter of 2023. First Quarter 2023 Financial Highlights • Total revenues of $160.3 million • Net product sales of $130.4 million for EXPAREL, $24.3 million for ZILRETTA, and $4.0 million for iovera° • Net loss of $19.5 million, or $0.43 per share (basic and diluted) •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000020/0001396814-23-000020-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Revenue","value":"$160.3 million"},{"label":"Net income","value":"$19.5 million"},{"label":"EPS","value":"$0.43 per share (basic and diluted)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}